A recent study reports that microglia and oligodendrocytes promote motor neuron degeneration by inducing inflammation and necroptosis in a manner dependent on receptor-interacting kinase 1 (RIPK1). These findings could be significant for our understanding of the neurobiology and treatment of neurodegenerative diseases like amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease in the USA, is the most common paralytic disorder in adults [1] . To date, there is no cure for ALS and, even when the cause is known, as in rare familial cases of the disease that are linked to mutations in particular genes, the mechanisms responsible for neurodegeneration remain enigmatic [1] . Studies in human post-mortem tissues from ALS patients and from mouse models of ALS have led to two insights about the neurobiology of this disease, however [2] . First, while damage to motor neurons is responsible for ALS paralysis, denervation of the neuromuscular junctions consistently precedes and exceeds the extent of loss of motor neuron cell bodies [2] , raising the idea that the ALS clinical picture results, first and foremost, from the degeneration of nerve terminals. Second, several lines of evidence support a role for glial cells in the demise of neighboring motor neurons, suggesting that the neurodegenerative process of ALS relies, at least in part, on non-cell-autonomous mechanisms [3] . In a recent study published in Science, Ito et al. [4] provide an exciting new twist in the biology of ALS whereby the reader is presented with the notion that two types of glia, namely microglia and oligodendrocytes, provoke the destruction of motor neuron axons via the activation of two distinct cellular processes dependent on receptorinteracting kinase 1 (RIPK1). How the authors arrived at this conclusion is in itself a fascinating journey. The beginning of this story commences with the characterization of a germline mutant mouse line that is constitutively deficient in Optineurin (Optn), a gene for which loss-of-function mutations have been linked to ALS [5] . These mice did not develop overt paralysis, shortened lifespan, or motor neuron death, as one would expect in a model of ALS [2] . However, the authors did note that, in the spinal ventrolateral white matter and to a lesser extent in the anterior roots, these mutant mice from the age of 3 weeks showed mild reductions in axon numbers, some axons of abnormally large diameter, and signs of thicker, less compact myelin sheaths ( Figure 1 ). These subtle axon-myelin abnormalities were associated with a number of TUNEL-positive cells (used as a marker of cell death) in the spinal white matter and with neuromuscular denervation at the level of the tibialis anterior, a muscle known to be innervated by motor neurons that are highly vulnerable to the ALS disease process [2] . One characteristic of neurodegenerative disorders is that the loss of neurons is restricted to specific subtypes and areas, even if the expression of the disease-causing gene defect is widespread [6] . Thus, since these mutant mice uniformly lack Optn in all cells throughout the body, it would have been interesting to know whether similar axon-myelin defects occurred in other regions of the nervous system, in particular the spinal posterior white matter and posterior roots.
While quite mild, the described phenotype of these particular mutant mice is consistent with pathology reminiscent of a demyelinating axonopathy, even though this conclusion cannot be reached with certainty in the absence of electromyography and conduction velocity studies. Nonetheless, the authors went on to use the described axon-myelin defect ( Figure 1 ) as a proxy for neuropathology driven by loss of Optn. However, whether this proxy could be considered as a marker of ALS pathology is debatable because such an axon-myelin defect has not, up to now, been identified as a common or prominent feature of this disease. Could it be that this axon-myelin defect represents a specific, and no less interesting, effect of Optn deficiency that is not found in sporadic ALS, which corresponds to more than 90% of all cases?
Since the gene product of Optn is ubiquitously expressed, Ito et al. [4] then asked whether the axon-myelin defect required a generalized or a cell-specific lack of Optn. By using a conditional mutant mouse that carries flox-Optn alleles and a series of cell-specific Cre lines, Ito et al. [4] excised Optn from specific cell types and found that the reduction of Optn expression in oligodendrocytes and myeloid cells, but not in astrocytes or motor neurons, reproduced the abnormal axon-myelin phenotype. Of note, thanks to a temporally specific inducible system, the authors showed that, even if Optn expression was maintained until 8 weeks of age, its deletion in young adults thereafter reproduces the abnormal axon-myelin phenotype after only one month. This demonstrated that microglia contribute to the abnormal axon-myelin phenotype via a degenerative process rather than a developmental defect.
Next, Ito et al. [4] sought to elucidate the molecular mechanism by which the lack of Optn leads to the observed pathological phenotype and, in thinking about their previous genome-wide siRNA screen, they remembered that silencing Optn sensitized L929 fibroblast-like cells to necroptosis upon exposure to the caspase inhibitor zVAD.fmk [7] . After validating the role of Optn loss in sensitizing cells to necroptosis in L929 cells and also in cultured fibroblasts, the authors found that the key molecular determinants of necroptosis -namely RIPK1, RIPK3 and the phosphorylated form of the mixed lineage kinase domainlike protein (MLKL) -were all increased in the spinal cord of Optn -/-mice. Also supportive of a role for necroptosis here is the observation that cultured Optndeficient oligodendrocytes died upon exposure to tumor necrosis factor a (TNFa) or zVAD.fmk but were protected against such death if RIPK1 kinase function was inhibited or if RIPK3 was deleted. Interestingly, Optn-deficient microglia were also the site of RIPK1 activation, but since these cells apparently express little MLKL, the recognized effector of necroptosis at least in immune cells, the authors suggest that RIPK1 promotes the production of pro-inflammatory mediators, rather than killing the cell. Consistent with this alternative idea, Ito et al. [4] detected increased levels of a variety of cytokines, including TNFa, in the spinal cord and in cultured microglia from Optn -/-mutant mice and found that these changes were abrogated in the absence of RIPK1 kinase activity. Based on these observations, the authors then targeted RIPK1 kinase function and RIPK3 in Optn -/-mutant mice and observed the mitigation of the axon-myelin phenotype, thus providing compelling evidence that RIPK1-dependent cell death and inflammation are both instrumental in driving the deleterious effects of Optn deficiency.
To assess whether the pathogenic scenario they discovered for Optn also applied to other causes of ALS, Ito et al. [4] evaluated transgenic mice expressing a mutant form of superoxide dismutase 1 (mSOD1), a mouse model of ALS that reproduces most of the hallmarks of the disease [2] . Remarkably, the authors found that 12-week-old transgenic mSOD1 mice -an age at which there is denervation but not yet motor neuron loss -exhibited the axon-myelin phenotype and had increased levels of RIPK1, RIPK3 and phospho-MLKL in the spinal cord, similar to Optn -/-mice. Even more striking are the observations that targeting RIPK1 and RIPK3 in transgenic mSOD1 mice not only attenuated the axon-myelin phenotype but also delayed the onset of motor defects. While the results with this second mouse model are exciting, it is not clear whether inhibiting RIPK1 extends the survival of these animals, which is probably the most important parameter, nor whether the role played by RIPK1 in the context of mSOD1 overexpression is the same as in the context of Optn deficiency. From this new work, it can be concluded that the consequences of a loss-of-function mutation in Optn are cell specific. For instance, within microglia, the lack of Optn function activates an intrinsic cascade that triggers microglia to adopt a RIPK1-dependent pro-inflammatory phenotype. According to the authors, this microglial response is assumed to kill neighboring oligodendrocytes by engaging necroptosis, another facet of RIPK1 activity (Figure 2 ). Yet, the notion of oligodendrocyte death here rests mainly on the use of the TUNEL assay, which is typically utilized to identify apoptosis not necroptosis and which is fraught with many false positives. Thus, given that oligodendrocyte cell death is so central to the proposed scenario, it would have been reassuring to see results from generic cell death assays, such as suppressed silver staining [8] .
Two additional enigmas are worth mentioning. First, if we were to extrapolate the insights gained in this study to human patients that carry Optn mutations even before birth, then it can be assumed that microglial activation and ensuing neurodegeneration should occur early in life and not, as in ALS, at adult age. Second, why should the assumed death of oligodendrocytes cause an axonopathy? Perhaps it is not their death but rather a preceding dysfunction that is critical in destroying axons, akin to the study of Viader et al. [9] where corrupted functions in Schwann cells, the peripheral analogues of oligodendrocytes, induced axonal degeneration in mice. From the above, it is thus clear that, in the pure tradition of research, the work from Ito et al. [4] sheds light on several new aspects of neurodegeneration, while at the same time raising a host of intriguing questions that hold promise for exciting future studies. In the spinal cord, Optn loss leads to an intrinsic sensitivity to RIPK1-dependent activation of microglia, leading to the release of pro-inflammatory cytokines including TNFa. Oligodendrocytes, sensitized by Optn loss to undergo RIPK1-dependent necroptosis, degenerate following stimulation by TNFa released from microglia. The death of oligodendrocytes leads to the observed formation of less compact myelin, increased denervation from nerve terminals, and axon degeneration.
